AWD-131-138. Anxiolytic, anticonvulsant

Drugs of the Future

Volumn 23, Issue 3, 1998, Pages 253-255

  Rostock, A ^a   Tober, C ^a   Dost, R ^a   Rundfeldt, C ^a   Bartsch, R ^a   Egerland, U ^a   Stark, B ^a   Schupke, H ^a   Kronbach, T ^a   Lankau, H J ^a   Unverferth, K ^a   Engel, J ^a  

^a ASTA MEDICA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 CHLOROPHENYL) 2,5 DIHYDRO 4 (4 MORPHOLINYL) 1 IMIDAZOLE 2 ONE; 1 (4 CHLOROPHENYL) 4 MORPHOLINO 3 IMIDAZOLIN 2 ONE; ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL EXPERIMENT; ANTICONVULSANT ACTIVITY; ANXIETY NEUROSIS; ARTICLE; CYCLIZATION; DRUG ACTIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; POLYMERIZATION; RAT; SEDATION; SEIZURE;

EID: 0031900848     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.03.450427     Document Type: Article

References (3)

1. Vogel, J.R., Beer, B., Clody, D.E. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 1971, 21: 1-7.
2. McNamara, J.O. Development of new pharmacological agents for epilepsy: Lessons from the kindling model. Epilepsia 1989, 30(Suppl. 1): S13-8.
3. Skeen, G.A., Wolf, H.H., White, S. AWD 131-138 enhances GABA-evoked whole cell currents in mouse cortical neurons. Epilepsia 1995, 36(Suppl. 4): Abst 2.63.